நீல் கரை News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from நீல் கரை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In நீல் கரை Today - Breaking & Trending Today
Arquer Diagnostics ADXBLADDER Becomes First Bladder Cancer Urine Test To Undergo Rigorous Clinical Trials In USA First patients recruited for bladder cancer recurrence monitoring study News provided by Share this article SUNDERLAND, England, July 27, 2021 /PRNewswire/ ADXBLADDER has become the first new generation urinary biomarker test for bladder cancer to undergo rigorous clinical trials in the USA in decades. The innovative and highly accurate test, developed by UK company Arquer Diagnostics, is already approved for use across Europe. ADXBLADDER is now being evaluated in a bladder cancer recurrence monitoring study in the US. With results of the study expected by the end of 2021, Arquer Diagnostics hopes to make a 510(k) premarket submission to the US Food and Drug Administration (FDA) to gain clearance from the organisation for ....
/PRNewswire/ LIPAC Oncology LLC., a pharmaceutical company utilizing its next generation precision liposomal technology to locally deliver taxanes to target. ....
Germline genetic testing can benefit all cancer patients as a routine practice in cancer care New data to be presented at 2021 ASCO Annual Meeting highlight need for increased germline testing in all cancer patients regardless of medical policy News provided by Share this article Share this article SAN FRANCISCO, May 25, 2021 /PRNewswire/ Invitae Corporation (NYSE: NVTA), a leading medical genetics company, is presenting multiple studies in multiple cancer types at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting showing all cancer patients can benefit from germline genetic testing to guide their care. The use of genetic information informs changes in cancer care, increases access to precision therapies and guides screening for high-risk individuals and their family members. Earlier detection and precision therapies are critical to increase survivorship for people with cancer, yet the oncology community has been slow to adopt routine ....
JAVELIN Bladder 100 Trial Interviews with Experts at Conferences Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information Videos April 23, 2021 November 17, 2020 November 16, 2020 October 14, 2020 Conference Coverage Conference Highlights from Recent Conference Coverage Petros Grivas, MD, PhD In Best of Podium presentation at this year’s Southeast Section of the American Urologic Association Virtual Annual Meeting, Dr. Grivas presented pre-specified subgroup analyses of the JAVELIN Bladder 100 trial. Read More Yohann Loriot, MD, PhD Avelumab first-line maintenance therapy is approved in the United States for patients with advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy based on significantly prolonged overall survival versus best supportive care alone (median 21.4 months versus 14.3 months; HR 0.69, 95% CI 0.56-0.86) as reporte ....
Sponsored Story By StoryStudio April 1, 2021 4:35 pm (BPT) – In the early part of the COVID-19 pandemic, many areas of the country banned nonessential medical procedures in an effort to slow the spread of the disease. As a result, many physicians saw fewer patients for routine medical care, such as physical exams and screenings. A recent survey by The Physicians Foundation polled 3,513 physicians and found 41% saw volume decreases of 26% or more in their practices. The impact on cancer screenings was even more profound. For example, screenings for prostate cancer one of the most commonly diagnosed cancers in men in the United States dropped by 56% by the peak of the pandemic in April according to a recent study published in ....